GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiwanJ Pharmaceuticals Co Ltd (ROCO:6549) » Definitions » Cash Ratio

TaiwanJ Pharmaceuticals Co (ROCO:6549) Cash Ratio : 9.57 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is TaiwanJ Pharmaceuticals Co Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. TaiwanJ Pharmaceuticals Co's Cash Ratio for the quarter that ended in Dec. 2023 was 9.57.

TaiwanJ Pharmaceuticals Co has a Cash Ratio of 9.57. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for TaiwanJ Pharmaceuticals Co's Cash Ratio or its related term are showing as below:

ROCO:6549' s Cash Ratio Range Over the Past 10 Years
Min: 2.63   Med: 9.11   Max: 44.38
Current: 9.57

During the past 11 years, TaiwanJ Pharmaceuticals Co's highest Cash Ratio was 44.38. The lowest was 2.63. And the median was 9.11.

ROCO:6549's Cash Ratio is ranked better than
80.19% of 1504 companies
in the Biotechnology industry
Industry Median: 2.97 vs ROCO:6549: 9.57

TaiwanJ Pharmaceuticals Co Cash Ratio Historical Data

The historical data trend for TaiwanJ Pharmaceuticals Co's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiwanJ Pharmaceuticals Co Cash Ratio Chart

TaiwanJ Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.66 13.45 12.10 8.65 9.57

TaiwanJ Pharmaceuticals Co Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.10 22.59 8.65 20.69 9.57

Competitive Comparison of TaiwanJ Pharmaceuticals Co's Cash Ratio

For the Biotechnology subindustry, TaiwanJ Pharmaceuticals Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiwanJ Pharmaceuticals Co's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiwanJ Pharmaceuticals Co's Cash Ratio distribution charts can be found below:

* The bar in red indicates where TaiwanJ Pharmaceuticals Co's Cash Ratio falls into.



TaiwanJ Pharmaceuticals Co Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

TaiwanJ Pharmaceuticals Co's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=58.829/6.146
=9.57

TaiwanJ Pharmaceuticals Co's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=58.829/6.146
=9.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiwanJ Pharmaceuticals Co  (ROCO:6549) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


TaiwanJ Pharmaceuticals Co Cash Ratio Related Terms

Thank you for viewing the detailed overview of TaiwanJ Pharmaceuticals Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiwanJ Pharmaceuticals Co (ROCO:6549) Business Description

Traded in Other Exchanges
N/A
Address
Rm. D207, Number 2, Sec.2, ShengYi Road, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei, TWN, 30261
TaiwanJ Pharmaceuticals Co Ltd is a Taiwan based specialty pharmaceutical company focused on small molecules for unmet medical needs like chronic organ inflammation of metabolic, autoimmune and infectious etiologies. It is also involved in developing novel chemical entities (NCEs) for chronic liver diseases and allergy/asthma.

TaiwanJ Pharmaceuticals Co (ROCO:6549) Headlines

No Headlines